Resources
87 Results (showing 51 - 60)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/24/2023 (updated 3/28/2024)
Welcome Webinar FY23 Child and Adolescent Behavioral Health
Posted 2/28/2023 (updated 3/27/2024)
In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals are strongly encouraged to report events in humans associated with xylazine exposure.
Posted 2/1/2023 (updated 3/27/2024)
This study looks at how common the presence of alcohol is in opioid overdose deaths. While there are "waves" of the opioid crisis, the authors studied how alcohol affect individuals in this fourth wave as it is characterized by opioid-stimulant polysubstance use.
Posted 10/23/2023 (updated 3/27/2024)
The 2023 RCORP-CABH Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA. We hope you find the Onboarding Packet helpful as a starting point. Our TA team is here to support you through your grant, so should you have any questions related to this document or other technical assistance needs, please do not hesitate to contact your Technical Expert Lead (TEL).
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 10/17/2023 (updated 3/27/2024)
This webinar will welcome FY23 Neonatal Abstinence Syndrome II recipients to the RCORP program, providing grantees an overview of the RCORP program, an introduction to HRSA’s Office of Federal Assistance Management, and information about the technical assistance and evaluation options for the award.
Posted 10/3/2023 (updated 3/27/2024)
This webinar will welcome RCORP-Overdose Response recipients to the RCORP program, providing grantees an overview of the RCORP program, an introduction to HRSA’s Office of Federal Assistance Management, and information about the technical assistance and evaluation options for the award.
Posted 6/7/2022 (updated 3/27/2024)
This presentation shared the experience of the Lenawee Substance Abuse Prevention Coalition’s evolution and experiences in the HRSA RCORP Planning and Implementation grants resulting in built capacities to implement robust strategic plans in response to Substance Use Disorder and Opioid Use Disorder within Lenawee County.
Posted 11/15/2022 (updated 3/27/2024)
… analytical model study evaluating the distribution of 10 000 additional naloxone kits annually in Rhode Island, the strategy focusing on distribution of naloxone according to geographic need to people who inject … both effectiveness and efficiency and reduce geospatial health inequality. … Neighbors … businesses … community …